Literature DB >> 19604308

Cytolytic mechanisms and T-cell receptor Vbeta usage by ex vivo generated Epstein-Barr virus-specific cytotoxic T lymphocytes.

Victoria J Vanhoutte1, Karen A McAulay, Erin McCarrell, Marc Turner, Dorothy H Crawford, Tanzina Haque.   

Abstract

Ex-vivo-generated Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes (CTL) have been used for cellular adoptive immunotherapy of EBV-associated lymphomas. Here we investigated the phenotypes, cytolytic mechanisms, polyfunctionality and T-cell receptor (TCR) usage in growing and established CTL, generated by weekly stimulation with an EBV-transformed autologous lymphoblastoid cell line (LCL). Our results showed that phenotypically mature CTL developed within the first 4 weeks of culture, with an increase in CD45RO and CD69, and a decrease in CD45RA, CD62L, CD27 and CD28 expression. Spectratyping analysis of the variable beta-chain of the TCR revealed that TCR repertoire remained diverse during the course of culture. Cytotoxicity of CTL was significantly inhibited by concanamycin A (P < 0.0001) and ethylene glycol-bis tetraacetic acid (P < 0.0001), indicating that a calcium and perforin-mediated exocytosis pathway with the release of granzyme B was the principal cytotoxic mechanism. The CTL mainly produced interferon-gamma (IFN-gamma) or tumour necrosis factor-alpha (TNF-alpha) upon restimulation with autologous LCL, although there were some polyfunctional cells producing IFN-gamma and TNF-alpha. Granzyme B, perforin and Fas ligand were detected in CD8(+) and CD4(+) cells in all CTL; however, a greater proportion of CD8(+) than CD4(+) T cells expressed granzyme B (P < 0.0001) and more granzyme B was detected in CD8(+) T cells than in CD4(+) T cells (P = 0.001). This difference was not observed with Fas ligand or perforin expression. Our results provide insight into the basic characteristics of ex-vivo-generated CTL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19604308      PMCID: PMC2729535          DOI: 10.1111/j.1365-2567.2008.03035.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  21 in total

1.  Primer3 on the WWW for general users and for biologist programmers.

Authors:  S Rozen; H Skaletsky
Journal:  Methods Mol Biol       Date:  2000

2.  CD8(+) T-cell selection, function, and death in the primary immune response in vivo.

Authors:  M F Callan; C Fazou; H Yang; T Rostron; K Poon; C Hatton; A J McMichael
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

Review 3.  The immunology of Epstein-Barr virus infection.

Authors:  D J Moss; S R Burrows; S L Silins; I Misko; R Khanna
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

Review 4.  T-cell quality in memory and protection: implications for vaccine design.

Authors:  Robert A Seder; Patricia A Darrah; Mario Roederer
Journal:  Nat Rev Immunol       Date:  2008-03-07       Impact factor: 53.106

5.  EBV persistence in memory B cells in vivo.

Authors:  G J Babcock; L L Decker; M Volk; D A Thorley-Lawson
Journal:  Immunity       Date:  1998-09       Impact factor: 31.745

6.  Cytotoxic cell granule-mediated apoptosis: perforin delivers granzyme B-serglycin complexes into target cells without plasma membrane pore formation.

Authors:  Sunil S Metkar; Baikun Wang; Miguel Aguilar-Santelises; Srikumar M Raja; Lars Uhlin-Hansen; Eckhard Podack; Joseph A Trapani; Christopher J Froelich
Journal:  Immunity       Date:  2002-03       Impact factor: 31.745

7.  Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication.

Authors:  Patrizia Comoli; Massimo Labirio; Sabrina Basso; Fausto Baldanti; Paolo Grossi; Milena Furione; Mario Viganò; Roberto Fiocchi; Giorgio Rossi; Fabrizio Ginevri; Bruno Gridelli; Antonia Moretta; Daniela Montagna; Franco Locatelli; Giuseppe Gerna; Rita Maccario
Journal:  Blood       Date:  2002-04-01       Impact factor: 22.113

8.  Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells.

Authors:  Tanzina Haque; Gwen M Wilkie; Clare Taylor; Peter L Amlot; Parvez Murad; Angela Iley; Dilani Dombagoda; Kate M Britton; Anthony J Swerdlow; Dorothy H Crawford
Journal:  Lancet       Date:  2002-08-10       Impact factor: 79.321

9.  CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines.

Authors:  H M Long; T A Haigh; N H Gudgeon; A M Leen; C-W Tsang; J Brooks; E Landais; E Houssaint; S P Lee; A B Rickinson; G S Taylor
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

10.  Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.

Authors:  C Münz; K L Bickham; M Subklewe; M L Tsang; A Chahroudi; M G Kurilla; D Zhang; M O'Donnell; R M Steinman
Journal:  J Exp Med       Date:  2000-05-15       Impact factor: 14.307

View more
  6 in total

1.  Epstein-Barr virus-specific CD8(+) T lymphocytes from diffuse large B cell lymphoma patients are functionally impaired.

Authors:  D Cárdenas; G Vélez; A Orfao; M V Herrera; J Solano; M Olaya; A M Uribe; C Saavedra; M Duarte; M Rodríguez; M López; S Fiorentino; S Quijano
Journal:  Clin Exp Immunol       Date:  2015-09-11       Impact factor: 4.330

2.  Immunotherapy for EBV-associated malignancies.

Authors:  Anna Merlo; Riccardo Turrini; Riccardo Dolcetti; Paola Zanovello; Antonio Rosato
Journal:  Int J Hematol       Date:  2011-02-19       Impact factor: 2.490

3.  Age-associated Epstein-Barr virus-specific T cell responses in seropositive healthy adults.

Authors:  D Cárdenas Sierra; G Vélez Colmenares; A Orfao de Matos; S Fiorentino Gómez; S M Quijano Gómez
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

4.  Impact of γ-chain cytokines on EBV-specific T cell cultures.

Authors:  Anna Merlo; Riccardo Turrini; Cristina Trento; Paola Zanovello; Riccardo Dolcetti; Antonio Rosato
Journal:  J Transl Med       Date:  2010-11-22       Impact factor: 5.531

5.  Assessment of T-cell receptor repertoire and clonal expansion in peripheral T-cell lymphoma using RNA-seq data.

Authors:  Qiang Gong; Chao Wang; Weiwei Zhang; Javeed Iqbal; Yang Hu; Timothy C Greiner; Adam Cornish; Jo-Heon Kim; Raul Rabadan; Francesco Abate; Xin Wang; Giorgio G Inghirami; Timothy W McKeithan; Wing C Chan
Journal:  Sci Rep       Date:  2017-09-12       Impact factor: 4.379

6.  Loss of T-Cell Multifunctionality and TCR-Vβ Repertoire Against Epstein-Barr Virus Is Associated With Worse Prognosis and Clinical Parameters in HIV+ Patients.

Authors:  Diana M Hernández; Sandra Valderrama; Sandra Gualtero; Catalina Hernández; Marcos López; Maria Victoria Herrera; Julio Solano; Susana Fiorentino; Sandra Quijano
Journal:  Front Immunol       Date:  2018-10-04       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.